

25 November 2010 EMA/HMPC/3203/2009 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Quercus robur* L., *Quercus petraea*.(Matt.) Liebl., *Quercus pubescens* Willd., cortex

Final

,
March 2009
September 2009
January 2010
14 January 2010
14 January 2010
1E May 2010
15 May 2010
September 2010
November 2010
25 November 2010

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Quercus robur L., Quercus petraea.(Matt.) Liebl., Quercus pubescens
	Willd., Quercus cortex; oak bark

BG (bălgarski):	LT (lietuvių kalba):
CS (čeština):	LV (latviešu valoda):
DA (dansk):	MT (malti):
DE (Deutsch):	NL (nederlands):
EL (elliniká):	PL (polski):
EN (English): oak bark	PT (português):
ES (espanol):	RO (română):
ET (eesti keel):	SK (slovenčina):
FI (suomi):	SL (slovenščina):
FR (français):	SV (svenska):
HU (magyar):	IS (íslenska):
IT (italiano):	NO (norsk):



Community herbal monograph on Quercus robur L., Quercus petraea.(Matt.) Liebl., Quercus pubescens Willd., cortex

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1,2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Quercus robur L., Quercus petraea (Matt.) Liebl. and Quercus pubescens Willd., cortex (oak bark)
	i) Herbal substance
	Not applicable
	ii) Herbal preparations
	a) Comminuted herbal substance
	b) Powdered herbal substance
	c) Dry extract (DER 5.0-6.5:1), extraction solvent ethanol 50% m/m

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as a herbal tea for oral use or as a decoction preparation for oromucosal or cutaneous use.
	Herbal preparation in solid or liquid dosage forms for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

The material complies with the Ph. Eur. monograph (ref. no 01/2008:1887).
 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product for symptomatic treatment of mild diarrhoea.
	Indication 2)
	Traditional herbal medicinal product for symptomatic treatment of minor inflammation of the oral mucosa or skin.
	Indication 3)
	Traditional herbal medicinal product for symptomatic relief of itching and burning associated with haemorrhoids, after serious conditions have been excluded by a medical doctor.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Adults, elderly
	Indication 1)
	a) 3 g comminuted herbal substance in 250 ml of water, three times daily.
	b) 1 g powdered herbal substance in capsules/tablets for oral use, three times daily.
	c) Dry extract: 140 mg, 4 times daily.
	Indication 2)
	a) Decoction for oromucosal use: 20 g/L.
	Indications 2) and 3)
	b) Decoction for bath preparation: 5 g comminuted herbal substance/1L to be added to the bath (bath duration 20

Well-established use	Traditional use
	minutes).
	One full or partial bath daily.
	Topical rinses or poultices several times daily.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4. 'Special warnings and precautions for use').
	Duration of use
	Indication 1)
	Not to be used for more than 3 days.
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indications 2) and 3)
	Not to be used for more than 1 week.
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.
	Cutaneous use.
	Oromucosal use.
	Anorectal use.

4.3. Contraindications

raditional use
Hypersensitivity to the active substance.
Use as bath additive: Open wounds, large skin and mucosa injuries and infection of the skin and mucosa.
ly Je

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data.
	Indication 1)
	If recurrent diarrhoea or bloody stools occur, a doctor or a qualified health care practitioner should be consulted.
	Indications 2) and 3)
	Hot bathes should not be used in case of febrile or infectious illnesses, in heart insufficiency and hypertension.
	Indication 3)
	If rectal bleeding occurs during the treatment of haemorrhoids a doctor should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	Indication 1)
	Internal absorption of concomitantly administered medicine may be delayed. For this reason, the product should be taken 1 hour or more before or after intake of other medicinal products.

4.6. Pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Allergic reactions have been reported. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.
	carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision
25 November 2010